VA-REGULA
3.4.2024 09:01:31 CEST | Business Wire | Press release
When it comes to verifying identity in remote scenarios, it’s generally through liveness checks that organizations try to ensure they are dealing with a real individual. Fraudsters are perfectly aware of this fact, and therefore seek to bypass verification using various tactics, predominantly presentation or injection attacks. The first type of fraud involves attempts to trick the system by presenting fake biometric traits, such as photos, videos, masks, etc. Injection attacks are done by inserting altered biometric data directly into the process of identity verification (IDV).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240403567119/en/
A presentation attack scenario blocked by Regula Face SDK (Photo: Business Wire)
To help organizations secure remote IDV processes, Regula offers powerful technologies capable of detecting even the most sophisticated biometric fraud, including presentation and injection attacks. This latest update marks an advancement in Regula’s ability to detect certain types of spoofing attacks.
Enhanced security. Now, Regula Face SDK, a comprehensive solution for biometric verification, has reached a 99% rate in detecting and blocking presentation attacks done from electronic devices. Its anti-spoofing technology ensures that the face detected during the verification process is from an actively present and real person.
Streamlined user experience. Also, the new release of Regula Face SDK brings a new level of usability to biometric verification, thanks to the introduction of Passive Liveness technology. Utilizing neural networks trained on a diverse dataset, this technology verifies the genuine presence of an individual without any active participation from users (unlike Active Liveness) – the solution just requires them to take a selfie.
To obtain proper data for verification, i.e., a high-quality face image, Regula Face SDK uses an advanced image capture module that assesses image quality in real time, reducing the need for retakes. Followed by an instant liveness check, this approach significantly streamlines the overall verification process, making it faster and more user-friendly while maintaining high security standards.
“Remote onboarding is our new reality. More risky for organizations and definitely more preferable for users, it is about finding the perfect balance between security and convenience. The Passive Liveness feature is a delicate solution to this equation. It’s a very accessible single step for the user, improving user experience and elevating conversion rates. But that’s not all: Passive Authentication still ensures a high level of trustworthiness in the IDV process, as it effectively proves the presence and realness of an individual. Plus, for those who need ultimate security during onboarding or user verification, there is still the option of choosing Active Liveness, a more user-involving and robust technology for proving liveness,” says Ihar Kliashchou, Chief Technology Officer at Regula.
For the sake of greater convenience and faster interaction, the updated Regula Face SDK also supports face matching on mobile devices, without transmitting data to a server. Now, even if a smartphone is offline, it is still possible to compare a photo from a document with a selfie when identity verification is done not remotely, but on-site by an employee, for example in a bank when a client wants to open an account or get access to other financial services.
To learn more about the capabilities of the new version of Regula Face SDK, visit the official webpage.
About Regula
Regula is a global developer of forensic devices and identity verification solutions. With our 30+ years of experience in forensic research and the largest library of document templates in the world, we create breakthrough technologies in document and biometric verification. Our hardware and software solutions allow over 1,000 organizations and 80 border control authorities globally to provide top-notch client service without compromising safety, security or speed. Regula was repeatedly named a Representative Vendor in the Gartner® Market Guide for Identity Verification.
Learn more at www.regulaforensics.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240403567119/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
